NasdaqCM - Nasdaq Real Time Price USD

Inhibikase Therapeutics, Inc. (IKT)

1.8200

-0.0700

(-3.70%)

As of 10:36:41 AM EDT. Market Open.

Hedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term losses

Key Insights Institutions' substantial holdings in Inhibikase Therapeutics implies that they have significant influence...

Simply Wall St. 6 days ago

IKT
-3.70%
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial HypertensionBOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (“PAH”), today reported financial results for the year ended December 31, 2024 and highlighted recent developments. “The

GlobeNewswire 13 days ago

IKT
-3.70%
Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Inhibikase Therapeutics (IKT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks last month

IKT
-3.70%
Inhibikase Announces Expansion of Senior Leadership Team

--- Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief Scientific Officer --- --- Vince Aurentz to join Inhibikase Board of Directors --- BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of two pharma industry executives with deep experience in pulmonary arterial hypertension (“PAH”) to its senior leadership team. Chris Cabell, M.

GlobeNewswire last month

IKT
-3.70%
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth

-- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of Mark Iwicki as the Company's Chief Executive Officer, replacing Dr. Milton H. Werner, founder of Inhibikase, effective February 14, 2025. Additionally, effective Febr

GlobeNewswire last month

IKT
-3.70%
Bullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of Stock

Quite a few insiders have dramatically grown their holdings in Inhibikase Therapeutics, Inc. ( NASDAQ:IKT ) over the...

Simply Wall St. 2 months ago

IKT
-3.70%
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

-- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension -- --201 Trial Results to be reported in 4Q2024 -- BOSTON and ATLANTA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of

GlobeNewswire 4 months ago

IKT
-3.70%
Inhibikase Therapeutics Secures Funding and Strengthens Leadership

Inhibikase Therapeutics ( (IKT) ) has shared an update. Inhibikase Therapeutics, Inc. has secured approximately $110 million through a private placement, boosting its potential financing to $275 million upon full exercise of warrants. This funding supports the Phase 2b trial of IkT-001Pro, aimed at treating Pulmonary Arterial Hypertension, signifying a pivotal step in the company’s mission to develop disease-modifying therapies. The closing also coincides with strategic board appointments, enhan

TipRanks 5 months ago

IKT
-3.70%
Perceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics Inc

On October 21, 2024, Perceptive Advisors LLC, a prominent investment firm, initiated a new position in Inhibikase Therapeutics Inc (NASDAQ:IKT), purchasing 8,194 shares at a price of $2.22 each. This transaction marks a significant new investment by the firm into the biotechnology sector, specifically targeting a company focused on innovative treatments for Parkinson's disease and related disorders. Perceptive Advisors LLC, based in New York, is known for its strategic investments primarily in the healthcare and financial services sectors.

GuruFocus.com 5 months ago

IKT
-3.70%
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 -- BOSTON and ATLANTA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Cardiopulmonary and Neurodegenerative disease through Abe

GlobeNewswire 5 months ago

IKT
-3.70%
Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc

On October 9, 2024, Fairmount Funds Management LLC (Trades, Portfolio) made a significant new investment in the biotechnology sector by purchasing 6,620,311 shares of Inhibikase Therapeutics Inc (NASDAQ:IKT). This transaction, executed at a price of $1.26 per share, marks a new holding for the firm and reflects a substantial commitment, as these shares now constitute 0.93% of their portfolio and 9.90% of the company's outstanding shares.

GuruFocus.com 5 months ago

IKT
-3.70%
Inhibikase Therapeutics Secures $110M for Drug Development

Inhibikase Therapeutics ( (IKT) ) has shared an update. Inhibikase Therapeutics, Inc. has entered into an agreement for a private placement transaction valued at approximately $110 million with institutional and accredited investors. The company plans to issue over 58 million shares of common stock, as well as pre-funded and Series Warrants, which are immediately exercisable at nominal prices. This strategic financial move is expected to bolster Inhibikase’s pursuit of advancing its lead drug ca

TipRanks 5 months ago

IKT
-3.70%
Steven Cohen's Strategic Acquisition of Inhibikase Therapeutics Shares

On October 9, 2024, Steven Cohen (Trades, Portfolio), through Point72 Asset Management, marked a significant transaction by acquiring 625,000 shares of Inhibikase Therapeutics Inc (NASDAQ:IKT). The total shares now held in IKT account for 8.40% of the company's outstanding shares, showcasing a substantial commitment to this biotechnology entity.

GuruFocus.com 5 months ago

IKT
-3.70%
Inhibikase Therapeutics Unveils PAH and Parkinson’s Drug Pipeline

Inhibikase Therapeutics ( (IKT) ) has provided an announcement. Inhibikase Therapeutics, Inc. released a new presentation on their website detailing the development of disease-modifying therapeutics for Pulmonary Arterial Hypertension (PAH). The company’s multi-therapeutic pipeline includes IkT-001Pro, a prodrug of imatinib mesylate with a significant market potential, and Risvodetinib for untreated Parkinson’s disease, with Phase 2 results expected soon. The presentation underscores the high un

TipRanks 5 months ago

IKT
-3.70%
Inhibikase Therapeutics Prices $110 Million Private Placement; Shares Jump

Inhibikase Therapeutics Prices $110 Million Private Placement; Shares Jump

PREMIUM
MT Newswires 5 months ago

IKT
-3.70%
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

-- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital -- BOSTON and ATLANTA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or the “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of cardiopulmonary and neurodegenerative disease through Abelson Tyrosine Kinase inhibition, today announced the pricing of an approxi

GlobeNewswire 5 months ago

IKT
-3.70%
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

Company to host conference call on August 15, 2024 at 8:00 a.m. ETBOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the second quarter ended June 30, 2024 and highligh

GlobeNewswire 7 months ago

IKT
-3.70%
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the second quarter ended June 30, 2024, on Wednesday, August 14, 2024, after the close of U.S. mark

GlobeNewswire 7 months ago

IKT
-3.70%
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease

Company expects to report trial results in 4Q24BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced the company has completed enrollment in the Phase 2 ‘201’ trial evaluating the safety and tole

GlobeNewswire 9 months ago

IKT
-3.70%
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced expansion of its therapeutic pipeline a

GlobeNewswire 9 months ago

IKT
-3.70%

Performance Overview

Return	IKT	S&P 500 (^GSPC)
YTD	-44.00%	-9.43%
1-Year	-15.35%	+3.22%
3-Year	-77.94%	+18.69%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Inhibikase Therapeutics, Inc. (IKT)

Hedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term losses

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Inhibikase Announces Expansion of Senior Leadership Team

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth

Bullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of Stock

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Secures Funding and Strengthens Leadership

Perceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics Inc

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc

Inhibikase Therapeutics Secures $110M for Drug Development

Steven Cohen's Strategic Acquisition of Inhibikase Therapeutics Shares

Inhibikase Therapeutics Unveils PAH and Parkinson’s Drug Pipeline

Inhibikase Therapeutics Prices $110 Million Private Placement; Shares Jump

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

Performance Overview